Poxvirus-vectored vaccines for rabies--a review (Q37635373)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Poxvirus-vectored vaccines for rabies--a review	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Poxvirus-vectored vaccines for rabies--a review (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

0 references

object named as

Louis H Nel

3

0 references

Charles Edward Rupprecht

2

object named as

Charles E Rupprecht

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Jacqueline Weyer

1

object named as

Jacqueline Weyer

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

language of work or name

0 references

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

7198-7201

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Recombinant vaccinia virus: immunization against multiple pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Poxviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Vaccinia virus: a selectable eukaryotic cloning and expression vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Expression of rabies virus glycoprotein from a recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Oral vaccination of the fox against rabies using a live recombinant vaccinia virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Vaccination of vampire bats using recombinant vaccinia-rabies virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Rabies challenge of captive striped skunks (Mephitis mephitis) following oral administration of a live vaccinia-vectored rabies vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Oral vaccination of dogs with recombinant rabies virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Human infection due to recombinant vaccinia-rabies glycoprotein virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Immunisation with canarypox virus expressing rabies glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

A single vaccine for the control of capripox infection in sheep and goats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Protection of goats against peste des petits ruminants with recombinant capripoxviruses expressing the fusion and haemagglutinin protein genes of rinderpest virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Immune responses to recombinants of the South African vaccine strain of lumpy skin disease virus generated by using thymidine kinase gene insertion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Overview of rabies in the Americas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Canine vaccination--providing broader benefits for disease control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Molecular epidemiology of rabies: focus on domestic dogs (Canis familiaris) and black-backed jackals (Canis mesomelas) from northern South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

A molecular epidemiological study of rabies epizootics in kudu (Tragelaphus strepsiceros) in Namibia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

New approaches to the prevention and eradication of rabies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Human adenovirus type 5 vectors expressing rabies glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

Naturally occurring orthopoxviruses: potential for recombination with vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.033

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.09.033

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37635373&oldid=1988167034"